共递送紫杉醇的纳米药物抑制乳腺癌转移的研究进展  

Research progress in the inhibition of breast cancer metastasis by co-delivering paclitaxel nanodrugs

作　　者：赵翠翠 张传桂 Zhao Cuicui;Zhang Chuangui(VIP Ward,Tianjin Medical University Cancer Institute and Hospital,National Clinical Research Center for Cancer,Key Laboratory of Cancer Prevention and Therapy,Tianjin's Clinical Research Center for Cancer,Tianjin 300060,China)

机构地区：[1]天津医科大学肿瘤医院特需病房,国家恶性肿瘤临床医学研究中心,天津市"肿瘤防治"重点实验室,天津市恶性肿瘤临床医学研究中心,乳腺癌防治教育部重点实验室,天津300060

出　　处：《国际生物医学工程杂志》2022年第4期345-349,共5页International Journal of Biomedical Engineering

基　　金：天津市医学重点学科(专科)建设项目(TJYXZDXK-009A)。

摘　　要：乳腺癌是全球新发病例最多的恶性肿瘤,在女性癌症相关死因中高居首位。超过九成的乳腺癌相关死亡与其转移有关。紫杉醇作为治疗乳腺癌最常用的化疗药物之一,是抑制乳腺癌转移的有效手段。为克服紫杉醇疏水性和其助溶剂带来的不良反应,其纳米药物一直是研究热点。一些递送紫杉醇的纳米药物已用于临床实践,且显示出令人满意的疗效和良好的耐受性。对共递送紫杉醇的纳米药物抑制乳腺癌转移的研究进展进行综述,为其抗乳腺癌转移的研究提供参考依据。Breast cancer is the malignancy with the highest number of new cases worldwide and is the leading cause of cancer-related deaths in women.More than 90%of breast cancer-related deaths are related to its metastasis.Paclitaxel,one of the most commonly used chemotherapeutic agents for the treatment of breast cancer,is an effective means of inhibiting breast cancer metastasis.To overcome the adverse effects of paclitaxel's hydrophobicity and its co-solvent,its nano-drugs have been a hot research topic.Some nanomedicines delivering paclitaxel have been used in clinical practice and have shown satisfactory efficacy and good tolerability.In this review,the research progress on the inhibition of breast cancer metastasis by co-delivered paclitaxel nanomedicines was summarized with the aim of providing a reference for their anti-breast cancer metastasis research.

关 键 词：紫杉醇 乳腺癌 纳米药物 共递送 

分 类 号：R737.9[医药卫生—肿瘤]